Lilly's Loxo Bet Pays Off In Thyroid Cancer, A Second Indication For Selpercatinib

 
• By Mandy Jackson

The company reported positive Phase III response rate data weeks after strong results in lung cancer for the RET inhibitor also known as LOXO-292. An NDA submission is on track for later this year.

Thyroid-cancer
Lilly will seek approval in RET-mutant medullary thyroid cancer. • Source: Shutterstock

More from Clinical Trials

More from R&D